The Cooper Companies, Inc. (NASDAQ:COO) Stock Position Trimmed by Oak Thistle LLC

Oak Thistle LLC decreased its position in The Cooper Companies, Inc. (NASDAQ:COO) by 47.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,635 shares of the medical device company’s stock after selling 4,179 shares during the period. Oak Thistle LLC’s holdings in Cooper Companies were worth $426,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Ashton Thomas Securities LLC acquired a new stake in Cooper Companies in the third quarter worth about $25,000. Covestor Ltd raised its position in shares of Cooper Companies by 144.9% during the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after buying an additional 200 shares in the last quarter. Brown Brothers Harriman & Co. lifted its stake in shares of Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares during the period. Friedenthal Financial bought a new position in shares of Cooper Companies in the third quarter valued at approximately $50,000. Finally, Cromwell Holdings LLC acquired a new position in shares of Cooper Companies during the third quarter valued at approximately $52,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Price Performance

Shares of COO stock opened at $92.04 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $18.37 billion, a price-to-earnings ratio of 47.20, a PEG ratio of 2.29 and a beta of 0.99. The firm’s 50 day moving average is $96.98 and its 200-day moving average is $98.89. The Cooper Companies, Inc. has a 1 year low of $84.76 and a 1 year high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter last year, the business posted $0.87 EPS. The firm’s revenue was up 9.8% compared to the same quarter last year. Sell-side analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on COO shares. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Wells Fargo & Company upped their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, December 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Citigroup cut their target price on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, December 6th. Finally, Morgan Stanley decreased their price target on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.